Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia

NCT01198067 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01198067
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01198067 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Pomalidomide in Relapsed or Refractory Waldenstrom Macroglobulinemia
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1
Overall status
Terminated
Start date
October 6, 2010
Completion date
May 2, 2025
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent waldenstrom macroglobulinemia, refractory waldenstrom macroglobulinemia